Preclinical evidence and mechanistic insights of ligustilide in ischemic stroke: a systematic review and meta-analysis

利古斯蒂利德治疗缺血性卒中的临床前证据和机制研究:系统评价和荟萃分析

阅读:2

Abstract

INTRODUCTION: Ligustilide, a phthalide-derived bioactive compound abundantly found in traditional Chinese medicinal herbs such as Angelica sinensis (Danggui) and Ligusticum chuanxiong (Chuanxiong), has attracted increasing attention for its potential therapeutic benefits in ischemic stroke (IS). However, its clinical applications remain limited, and the comprehensive preclinical evidence regarding its efficacy and mechanisms of action is still unclear. MATERIALS AND METHODS: A systematic search of PubMed, Web of Science, and Embase was conducted to identify preclinical studies evaluating the effects of Ligustilide in IS animal models. A meta-analysis was performed to quantitatively assess the efficacy of Ligustilide in reducing infarct volume and improving neurological function. Additional analyses explored its potential mechanisms and the sources of heterogeneity. RESULTS: The pooled results from 13 studies demonstrated that Ligustilide significantly reduced infarct volume (SMD = 3.26, 95% CI [2.31, 4.22], P < 0.05) and improved neurological scores (SMD = 1.64, 95% CI [1.13, 2.15], P < 0.05) in animal models of IS compared to control groups. Mechanistically, Ligustilide exerted protective effects by alleviating oxidative stress [lowering Malondialdehyde (MDA) levels (n = 3) and enhancing Superoxide Dismutase (SOD) (n = 2) and Glutathione (GSH) (n = 2) levels], suppressing inflammatory responses [reducing Tumor Necrosis Factor-alpha (TNF-α) (n = 3)], and a non-significant trend toward reduced apoptosis was also noted based on TUNEL staining (n = 2, P = 0.054), warranting further investigation. Sensitivity analyses confirmed the robustness of the findings. Subgroup analyses indicated that heterogeneity might be associated with differences in modeling methods, administration routes, and the use of multiple intervention doses. CONCLUSION: This systematic review and meta-analysis provides comprehensive preclinical evidence supporting the protective effects of Ligustilide in IS animal models through multi-target mechanisms. Future large-scale, high-quality animal studies and clinical trials are needed to further validate its therapeutic potential and facilitate its translational application.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。